EA200901213A1 - КОМБИНАЦИЯ ИНГИБИРОВАНИЯ BLyS И/ИЛИ APRIL И ИММУНОСУПРЕССАНТОВ ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОЙ БОЛЕЗНИ - Google Patents

КОМБИНАЦИЯ ИНГИБИРОВАНИЯ BLyS И/ИЛИ APRIL И ИММУНОСУПРЕССАНТОВ ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОЙ БОЛЕЗНИ

Info

Publication number
EA200901213A1
EA200901213A1 EA200901213A EA200901213A EA200901213A1 EA 200901213 A1 EA200901213 A1 EA 200901213A1 EA 200901213 A EA200901213 A EA 200901213A EA 200901213 A EA200901213 A EA 200901213A EA 200901213 A1 EA200901213 A1 EA 200901213A1
Authority
EA
Eurasian Patent Office
Prior art keywords
blys
fusion protein
april
extracellular domain
treatment
Prior art date
Application number
EA200901213A
Other languages
English (en)
Other versions
EA030313B1 (ru
Inventor
Рафаэл А. Джр. Понс
Уэйн Дж. Уоллис
Маттью С. Холдрен
Линда Зукерман
Алиса М. Литто
Керк П. Ван-Несс
Клаудиа Пена-Росси
Ханс-Отто-Леннарт Граффнер
Original Assignee
Займодженетикс, Инк.
Арес Трейдинг С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Займодженетикс, Инк., Арес Трейдинг С.А. filed Critical Займодженетикс, Инк.
Publication of EA200901213A1 publication Critical patent/EA200901213A1/ru
Publication of EA030313B1 publication Critical patent/EA030313B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Изобретение касается новых комбинированных терапий, включающих ингибирование BLyS или BLyS/APRIL и иммуносупрессанты для лечения аутоиммунных болезней. Один предпочтительный способ представляет собой способ, в котором антагонист BLyS и/или APRIL представляет собой Fc-слитый белок, который может быть TACI-Fc-слитым белком, включающим внеклеточный домен ТАСI, или его функциональным фрагментом, BAFF-R-Fc-слитым белком, включающим внеклеточный домен BAFF-R, или его функциональным фрагментом или BCMA-Fc-слитым белком, включающим внеклеточный домен ВСМА, или его функциональным фрагментом. В способах настоящего изобретения некоторые из рассмотренных иммуносупрессивных препаратов включают циклофосфамид (CYC), азатиоприн (AZA), циклоспорин (CSA) или микофенолят мофетил (MMF), хотя может быть подходящим любой препарат, который угнетает иммунную систему. Способы настоящего изобретения уменьшают уровни различных иммуноглобулинов у пациентов, которые нуждаются в таком снижении, таких как пациенты, страдающие от аутоиммунных болезней.
EA200901213A 2007-03-27 2008-03-27 СПОСОБ СНИЖЕНИЯ УРОВНЕЙ IgM, IgG И IgA У МЛЕКОПИТАЮЩИХ И КОМПОЗИЦИЯ ДЛЯ ОСУЩЕСТВЛЕНИЯ ЭТОГО СПОСОБА EA030313B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90836507P 2007-03-27 2007-03-27
PCT/US2008/058486 WO2008119042A2 (en) 2007-03-27 2008-03-27 Combination of blys inhibition and/or april inhibition and immunnosuppressants for treatment of autoimmune disease

Publications (2)

Publication Number Publication Date
EA200901213A1 true EA200901213A1 (ru) 2010-04-30
EA030313B1 EA030313B1 (ru) 2018-07-31

Family

ID=39789276

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901213A EA030313B1 (ru) 2007-03-27 2008-03-27 СПОСОБ СНИЖЕНИЯ УРОВНЕЙ IgM, IgG И IgA У МЛЕКОПИТАЮЩИХ И КОМПОЗИЦИЯ ДЛЯ ОСУЩЕСТВЛЕНИЯ ЭТОГО СПОСОБА

Country Status (19)

Country Link
US (2) US8852591B2 (ru)
EP (1) EP2139517B1 (ru)
JP (1) JP5426531B2 (ru)
CN (1) CN101678106B (ru)
AU (1) AU2008230777B8 (ru)
CA (1) CA2681728C (ru)
DK (1) DK2139517T3 (ru)
EA (1) EA030313B1 (ru)
ES (1) ES2422479T3 (ru)
HK (1) HK1138502A1 (ru)
HR (1) HRP20130725T1 (ru)
IL (1) IL201114A (ru)
MX (1) MX2009010125A (ru)
PL (1) PL2139517T3 (ru)
PT (1) PT2139517E (ru)
RS (1) RS52888B (ru)
SI (1) SI2139517T1 (ru)
WO (1) WO2008119042A2 (ru)
ZA (1) ZA200906808B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ES2609016T3 (es) * 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
NZ597082A (en) * 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
US8211649B2 (en) * 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
US20110014190A1 (en) * 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
WO2010126898A1 (en) * 2009-04-27 2010-11-04 The Trustees Of The University Of Pennsylvania Methods for reducing the level of alloantibodies in a subject
PE20181523A1 (es) * 2010-03-03 2018-09-24 Teva Pharma Tratamiento de lupus nefritis usando laquinimod
CN101851278B (zh) * 2010-05-26 2013-03-13 石药集团中奇制药技术（石家庄）有限公司 B细胞激活因子拮抗剂及其制备方法与用途
US10017762B2 (en) 2010-11-24 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
CA2818712C (en) * 2010-11-24 2020-11-10 Government Of The U.S.A. Represented By The Secretary, Dept. Of Health & Human Services Compositions and methods for treating or preventing lupus
CN102085367B (zh) * 2011-01-19 2012-08-22 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白用于制备治疗类风湿性关节炎药物的应用
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
CN103169966B (zh) * 2013-04-09 2015-04-01 中国人民解放军军事医学科学院基础医学研究所 一种治疗系统性红斑狼疮的药物组合物
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
MX2016010128A (es) 2014-02-07 2017-02-02 Univ Mcmaster Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo.
CN103936833B (zh) * 2014-04-18 2016-02-10 天津大学 BLyS拮抗肽、含TC-Fc融合蛋白基因的质粒及TC-Fc融合蛋白
CN103965295B (zh) * 2014-04-18 2015-12-02 天津大学 BLyS拮抗肽、含TA-Fc融合蛋白基因的质粒及TA-Fc融合蛋白
US10562954B2 (en) * 2014-05-12 2020-02-18 Shanghai Kanda Biotechnology Co., Ltd. Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
KR20180091849A (ko) * 2015-11-25 2018-08-16 비스테라, 인크. April에 대한 항체 분자 및 이의 용도
CN107586339B (zh) * 2016-07-06 2023-01-20 尚华科创投资管理（江苏）有限公司 一种BLyS抗体及其制备方法和应用
CA3078637A1 (en) 2017-10-12 2019-04-18 Mcmaster University T cell-antigen coupler with y182t mutation and methods and uses thereof
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
EP3843775B1 (en) * 2018-08-30 2024-04-03 The Governing Council of the University of Toronto Baff polypeptide for use in treating multiple sclerosis
EP3883593B1 (en) * 2018-11-21 2024-03-06 The Governing Council of the University of Toronto Baff polypeptide for use in treating multiple sclerosis
WO2020210670A1 (en) * 2019-04-12 2020-10-15 Biograph 55, Inc. Compositions and methods for cancer immunotherapy
US20230144779A1 (en) * 2019-12-20 2023-05-11 Vyome Therapeutics Inc. Formulations and method for treatment of inflammatory diseases
WO2021128027A1 (zh) * 2019-12-24 2021-07-01 荣昌生物制药(烟台)股份有限公司 TACI-Fc融合蛋白及其用途
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
CN115996748A (zh) * 2020-05-29 2023-04-21 奇努克医疗公司 用APRIL结合抗体治疗IgA肾病的方法
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
WO2023016444A1 (zh) * 2021-08-10 2023-02-16 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗IgA肾病的方法
WO2023019223A2 (en) * 2021-08-11 2023-02-16 Akso Biopharmaceutical Inc. METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF
CA3236667A1 (en) * 2022-06-08 2023-12-14 Jianmin Fang Method for treating myasthenia gravis with taci-fc fusion protein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2267593T3 (es) * 2000-02-16 2007-03-16 Genentech, Inc. Anticuerpos anti-april y celulas hibridomas.
AU2006201471B2 (en) 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
DK1436003T3 (da) 2001-05-24 2010-03-15 Zymogenetics Inc TACI-immunoglobulin-fusionsproteiner
AU2002322301A1 (en) * 2001-06-26 2003-03-03 Gene Logic, Inc. Methods for the diagnosis and treatment of cardiac tissue rejection
HUP0500992A3 (en) * 2001-08-03 2007-11-28 Genentech Inc Tacis and br3 polypeptides and uses thereof
WO2003055979A2 (en) * 2001-11-16 2003-07-10 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
MX2007005378A (es) * 2004-11-04 2008-02-14 Genentech Inc Polipeptidos que ligan a baff y/o april.
KR20070102670A (ko) 2004-11-17 2007-10-19 앤지오젠 파마슈티칼스 피티와이. 리미티드 Ｂ 세포 기능 조절방법
EP1924286A4 (en) * 2005-08-12 2010-01-13 Garvan Inst Med Res PROPHYLACTIC AND / OR THERAPEUTIC METHOD FOR THE TREATMENT OF AUTOIMMUNE DISEASES
BRPI0711823A2 (pt) * 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
CA2705357C (en) 2007-11-12 2018-10-23 Ares Trading S.A. Formulations for taci-immunoglobulin fusion proteins

Also Published As

Publication number Publication date
JP2010522767A (ja) 2010-07-08
AU2008230777B8 (en) 2014-07-03
CA2681728C (en) 2015-12-22
US20150017164A1 (en) 2015-01-15
RS52888B (en) 2014-02-28
AU2008230777A8 (en) 2014-07-03
PT2139517E (pt) 2013-07-11
US20080260737A1 (en) 2008-10-23
DK2139517T3 (da) 2013-08-26
HRP20130725T1 (en) 2013-10-11
MX2009010125A (es) 2010-02-17
HK1138502A1 (en) 2010-08-27
AU2008230777A1 (en) 2008-10-02
EP2139517B1 (en) 2013-05-29
SI2139517T1 (sl) 2013-09-30
ZA200906808B (en) 2011-10-26
JP5426531B2 (ja) 2014-02-26
WO2008119042A2 (en) 2008-10-02
CN101678106B (zh) 2013-06-05
AU2008230777B2 (en) 2014-02-27
IL201114A (en) 2014-01-30
ES2422479T3 (es) 2013-09-11
PL2139517T3 (pl) 2013-10-31
EP2139517A2 (en) 2010-01-06
CN101678106A (zh) 2010-03-24
IL201114A0 (en) 2010-05-17
EA030313B1 (ru) 2018-07-31
CA2681728A1 (en) 2008-10-02
US8852591B2 (en) 2014-10-07
WO2008119042A3 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
EA200901213A1 (ru) КОМБИНАЦИЯ ИНГИБИРОВАНИЯ BLyS И/ИЛИ APRIL И ИММУНОСУПРЕССАНТОВ ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОЙ БОЛЕЗНИ
CY1123734T1 (el) Καταστολη συμπληρωματος για βελτιωμενη αναγεννηση νευρου
González et al. Modafinil improves methamphetamine-induced object recognition deficits and restores prefrontal cortex ERK signaling in mice
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
WO2008064321A3 (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
Ferro et al. Cyclo‐Gly‐Pro, a cyclic dipeptide, attenuates nociceptive behaviour and inflammatory response in mice
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
TW200716172A (en) Pharmaceutical compositions for treating lower motor neuron diseases
Serata et al. Are 5‐HT3 antagonists effective in obsessive–compulsive disorder? A systematic review of literature
WO2006036729A3 (en) USE OF TGF-β ANTAGONISTS TO LIMIT NEPHROTOXICITY OF IMMUNOSUPPRESSIVE AGENTS
EA200802381A1 (ru) Лечение желудочно-кишечных расстройств антагонистами cgrp-пептида
WO2007096396A3 (en) Methods for treating autoimmune or demyelinating diseases
Ding et al. Drug-induced chronic cough and the possible mechanism of action
Oosting et al. Vilazodone does not inhibit sexual behavior in male rats in contrast to paroxetine: a role for 5-HT1A receptors?
WO2007034490A3 (en) Diastereomeric peptides for modulating t cell immunity
Segarra Medrano et al. Efficacy and safety of combined cyclosporin A and mycophenolate mofetil therapy in patients with cyclosporin-resistant focal segmental glomerulosclerosis
Pelayo et al. Localisation and activation of the neurokinin 1 receptor in the enteric nervous system of the mouse distal colon
Srivastava et al. Current Update on Evidence based Literature ofTofisopam
Stenberg et al. Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia–a path model investigation
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure
MA32129B1 (fr) Cyclosporine non immunosuppressive pour le traitement de la dystrophie musculaire
Smyth et al. Coincident membranous glomerulonephritis and chronic inflammatory demyelinating polyradiculoneuropathy: questioning the autoimmunity hypothesis

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM